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Design of Cyclic-ADT Peptides to Improve Drug Delivery to the Brain via Inhibition of 
E-Cadherin Interactions at the Adherens Junction 
©Marlyn Dian Laksitorini 
Abstract 
 
We have developed linear cadherin peptides (i.e., HAV- and ADT peptides) hat enhance brain 
delivery of drug molecules to the central nervous system (CNS). These peptides modulate 
cadherin interactions in the adherens junctions of the vascular endothelial cells in the blood-brain 
barrier (BBB) to increase paracellular drug permeation. In this study, the goal was to design 
cyclic peptides (ADTC1, ADTC5, and ADTC6) derived from linear ADT6 (Ac-ADTPPV-NH2) 
to improve their stability and biological activity in improving paracellular delivery of drugs into 
the brain. The ADTC1 peptide (cyclo(1,8)Ac-CADTPPVC-NH2) was designed by adding two 
Cys residues at the N- and C-terminus of ADT6 peptide and a disulfi e bond from thiol groups 
of the Cys residues. The ADTC5 peptide (cyclo(1,7)Ac-CDTPPVC-NH2) was derived from 
ADTC1 by deleting the alanine residue from the N-terminal region of ADTC1 and ADTC6. 
(Cyclo(1,6)Ac-CDTPPC-NH2) was constructed by deleting the valine residue from the C-
terminal region of ADTC5. The results showed that ADTC1 has activity n inhibiting the 
resealing of the intercellular junctions of the MDCK cell monolayers similar to that of the linear 
ADT6, indicating that cyclization can maintain the peptide activity. The alanine residue deletion 
in ADTC5 does not reduce its activity compared to ADTC1 peptide, suggesting that the alanine 
residue does not have an important role in the activity of the peptide. In contrast, ADTC6 peptide 
does not have activity in inhibiting the junction resealing, indicating that the valine residue is 
important for peptide activity. ADTC5 inhibits the junction resealing of MDCK cell monolayers 
in a concentration-dependent manner with the saturation concentration above 0.4 mM and IC50 
around 0.3 mM. Under the current experimental conditions, ADTC5 improves the deliv ry of 
14C-mannitol to the brain about two fold compared to the vehicle negative control in the in situ 
rat brain perfusion model. Furthermore, ADTC5 peptide does not enhance the BBB passage of 
large polyethylene glycol molecules(i.e., PEG-1500 and PEG-40000) in an situ rat brain 
perfusion model. In conclusion, formation of cyclic peptides can maintain c dherin peptide 
ability to modulate intercellular junctions of the BBB, and the prima y sequence of ADT 
peptides is important for their biological activity. 
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1. INTRODUCTION 
Delivering drugs to the brain to treat brain diseases is challenging; this is due to the 
presence of the blood brain barrier (BBB), which prevents drug transport from the systemic 
circulation into the brain. Most small and macromolecule drugs can not readily cross the BBB 
into the brain [1]; this is due to the presence of tight junctions [2], efflux pumps [3, 4], and many 
metabolism enzymes [5, 6]. Because of their physicochemical properties, peptide and protein 
drugs cannot readily partition into the cell membranes of endothelial c ls and penetrate the BBB 
passively via the transcellular route [7]. The transcellular pathway of drug transport is also 
limited by the presence of the efflux pump system, which recognizes a wide variety of drug 
molecular structures [3]. Finally, the paracellular transport of drug molecules with hydrodynamic 
diameter larger than 11 angstroms or 500 daltons molecular weight is limited by the presence of 
tight junctions [8]. Peptide-metabolizing enzymes were more pronounced in the cerebral 
microvasculature than in whole brain homogenates [5]; therefore, peptide and protein drugs 
maybe degraded prior to crossing the BBB, preventing the intact drugs from entering the brain. 
In addition, cytochrome P450 enzymes are expressed at very high levels in the brain astrocytes 
border, and they metabolize 70–80% of currently used drugs to prevent them from crossing the 
BBB into the brain parenchyma [6]. 
Many efforts have been made to cure brain diseases by improving brai  delivery of drugs 
[1, 8, 9]. For example, intracerebro-ventricular injection may provide h gh drug bioavailability 
(e.g., close to 100%) in the brain; however, the drug level drops drastically with respect to 
distance because of cerebrospinal fluid (CSF) diffusivity. Therefore, it requires injections at 
multiple sites to achieve sufficient drug efficacy [10]. Improving the transcellular drug 
permeation across the BBB has been extensively studied; one of the me ods is via cationization 
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of biopharmaceutical drugs to improve the adsorptive-mediated transcytosis [11]. The presence 
of insulin, transferrin, and nicotinic acetylcholine receptors in endothelial cells has been 
exploited to improve brain delivery via drug conjugation to monoclonal antibodies (mAbs) that 
bind to human insulin and transferrin receptors [1], while conjugation to rabies virus 
glycoprotein peptide (RVG29) has been used to target the acetylcholine receptor [12]. However, 
saturation of these receptors during receptor-mediated transcytosis may become a limitation for 
efficient drug delivery through the BBB. Another method to improve drug elivery through the 
BBB is enhancing drug permeation through intercellular junctions. Interferring phosphorylation 
of intercellular junction proteins causes relocation of some proteins at the adherens and tight 
junctions; this protein relocation generates opening of the paracellulr pathways [13]. However, 
the development of phosphorylation inhibitors as adjuvants to improve paracellul r drug 
permeation is limited by the non-specificity of phosphorylation inhibitors and the complexity of 
phosphorylation pathways. 
Our group investigates cadherin peptides that can inhibit cell-cell adhesion in the 
adherens junctions of the BBB.HAV peptides derived from the sequence of extracellular-1 (EC-
1) domain of E-cadherin have been shown to modulate the paracellular permeation of cell 
monolayers [14, 15]. An HAV peptide, Ac-SHAVSS-NH2, has also been shown to improve the 
paracellular permeation of 14C-mannitol and 3H(G)-daunomycin through the BBB using an in 
situ rat brain perfusion model [16]. ADT-6 peptide was derived from the EC1 domain of E-
cadherin as a counter-sequence of the HAV sequence on the EC1 domain. ADT-6 peptide was 
found to modulate the intercellular junctions of Madin-Darby Canine Kidney (MDCK) cell 
monolayers and enhance paracellular permeation of 14C-mannitol through cell monolayers. In 
cell monolayers, the size of ADT peptide can influence its activity because the peptide has to 
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pass through the tight junctions before it can inhibit cadherin-cadherin interaction at the adherens 
junctions. ADT hexapeptide was active when added from the apical side of the cell monolayers. 
In contrast, an ADT decapeptide was not effective in modulating intercellular junctions when it 
was added from the apical site; this is possibly due its inability to penetrate the tight junctions. 
Because of the absence of tight junctions on the basolateral side of MDCK cell monolayers, an 
ADT decapeptide can modulate the adherens junction from that side [15].  
In the present work, three cyclic ADT peptides (Table 1) were design d to improve 
stability and modulatory activity and to evaluate the effects of residue deletion and size of cyclic 
peptides on their biological activity.   
 
Table 1: Sequence of E-cadherin peptides.  
Bold C indicates cysteine residues that form a disulfide bond to create a 
cyclic peptide. 
Name Sequences MW determined by MS  
ADT6 Ac-ADTPPV-NH2 639.72 
ADTC1 Ac-CADTPPVC-NH2 844.00 
ADTC5 Ac-CDTPPVC-NH2 773.94 
ADTC6 Ac-CDTPPC-NH2 673.78 
KKLVPR Ac-KKLVPR-NH2 724.93 
 
 
To form the ADTC1 cyclic peptide, two cysteine residues were addd to the N- and C-termini, 
respectively, of ADT6; then an intramolecular disulfide bond was generated from the N- to the 
C-terminus Cys residues. The alanine residue from the N-terminus of ADT6 was deleted to make 
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ADTC5 for evaluating the effect of the Ala residue on its activity. Finally, the valine residue was 
deleted from ADTC5 to produce ADTC6 to test the effect of C-terminal valine residue on the 
activity of peptide. The biological activity of cyclic peptides in modulating the intercellular 
junctions was evaluated by measuring the change in transepithelial el ctrical resistance (TEER) 
values of MDCK cell monolayers in the presence of peptides. The en ancement of paracellular 
permeation of marker molecules through the BBB of an in situ rat brain perfusion model by these 
cyclic peptides was evaluated. 
 
2. MATERIALS AND METHODS 
2.1. Peptide synthesis 
Peptides were synthesized using Fmoc chemistry and a Perceptive Peptide synthesizer as 
previously described [15]. The purification was done by reversed-phase HPLC using a C-18 
semi-preparative column. Mass spectrometry was used to determine the correct molecular weight 
of each peptide. Cyclic peptides were formed via oxidation of the thiol groups of the N- and C-
terminus Cysresidues. All of the peptides had a purity of ≥ 95% as confirmed by reversed-phase 
analytical HPLC using a C-18 column. 
 
2.2. Cell culture 
Madin-Darby Canine Kidney (MDCK) cell strain-2 obtained from ATCC (Rockville, 
MD, USA) was grown in 75 cm2 Corning polystyrene flasks (Corning, NY, USA). Dulbecco’s 
modification of Eagle’s medium (Cellgro, Manasas, VA, USA) enriched with 10% fetal bovine  
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serum (Atlanta Biologicals, Lawrenceville, VA, USA), 100 units/ml penicilline, and 100 µg/ml 
streptomycin (Atlanta Biologicals), and 1.42 g/l HEPES sodium was used to culture the cells. 
The cells were incubated at 37°C, 95% humidity and 5% CO2. The medium was changed three 
times a week, and the cells were trypsinized with 0.25% trypsin in 1.0 mM EDTA (Atlanta 
Biologicals). One-tenth of the harvest cells were seeded in a new polystyrene flask.  
2.3. Resealing assay 
MDCK cells were seeded at 100.000 cells/well in 0.4 µm polyethylene membrane 
Transwells (Costar, Cambridge, MA, USA) with diameters of 1.12 cm2. The medium was 
changed every other day until the monolayer had TEER values above 300 Ohm.cm2 between 
days 5and 7. The monolayers were washed three times with medium A (Hank’s balances salt 
solution (HBSS), pH 7.4, enriched with 10 mM HEPES, 1% glucose, and 2.0 mMCaCl2). The 
last washing solution was kept in the wells for 1.5 hours to equilibrate the cells before TEER 
measurements. TEER values were measured at the end of the equilibration time, which was 
defined as t = 0 hour. To open the intercellular junctions, equilibrated monolayers were washed 
three times with medium B (the same as medium A but without CaCl2) and incubated for 1.0 
hours using the last washing solution. At the end of the incubation, TEER values were measured 
using EVOM2 (World Precision Instrument, Sarasota, FL) as t = 1 hour. F llowing the junction 
opening, the apical and basolateral chambers were incubated in 1.0 mM peptide dissolved in 
buffer A. The change in TEER value was measured every hour up to 6 hours. Buffer A and non-
cadherin peptide (i.e., KKVPR) were used as a negative control. The experiment was performed 
at least in triplicate. 
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2.4. In situ rat brain perfusion 
Rats (55–60 days old) were kept in The Animal Care Unit, The University of Kansas, 
under free access to food and water. The in situ rat brain perfusion was performed according to a 
Takasato publication with some modifications [17]. Briefly, rats were anesthetized 
intraperitoneally with 100 mg/kg of ketamine and 5 mg/kg of xylazine. Polyethylene catheters 
(PE 50) containing heparin-saline (10 IU/ml) were used to cannulate the left common carotid 
artery (LCCA), and retrograde perfusion was performed to prevent coagulation. During 
cannulation of the LCCA, the left pteryopalatine, occipital, and superior thyroid arteries were 
ligated. A heat lamp was used to maintain therat’s body temperatur . Before perfusion, rats were 
decapitated with cardiac puncture. The LCAA was washed for 10 sec u ing heparin-saline 
solution followed by 10ml perfusion of 1.0 mM peptide dissolved in HCO3-buffered 
physiological saline containing 0.5% v/v Tween 20. The HCO3-buffered physiological saline was 
composed of 142 µmol/ml NaCl, 28.0 µmol/ml NaHCO3, 4.2 µmol/ml KH2PO4, 1.7 µmol/ml 
CaSO4, and 1.0 µmol/ml MgSO4 and was aerated with 5% CO2 at 37ºC temperature and 95% 
humidity prior to the experiment. Following the peptide perfusion, 10 µCi14C-mannitol 
(Moravek Biochemicals, Brea, CA) dissolved in heparin-saline solution containing 0.5% v/v 
Tween 20 was delivered.  At the end of perfusion, a 10-sec post-perfusion wash using saline-
heparin solution was performed to remove the excess 14C-mannitol in the brain microvessels.  
All perfusions were done at 5 ml/sec rate using an infusion pump (Model 355 syringe pump, 
Sage Instrument, Boston, MA). Rat brain was removed from the skull and divided into three 
parts. Each part of the brain was weighed and ground. Four milliliters of scintillation fluid 
(Fisher Scientific, Morris Plains, NJ, USA) was added to each s mple. The radioactive activity 
was measured using a dual-double scintillation spectrometer (Beckman LS 6000 IC). 
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Transport studies with polyethylene glycol (PEG) molecules were p rformed using the 
same techniques as described above. 1,2-3H-PEG-1500 and 1,2-14C-PEG-40000 (American 
Radioactive Chemicals, St. Louis, MO) with strength 10 µCi/rat were used to evaluate the limits 
of pore-size openings created by cadherin peptides in in s tu rat brain perfusion experiments. 
 
3. RESULTS 
 
3.1. Effect of cyclic peptide formation and residue deletion on biological activity 
The biological activities of a linear peptide (i.e., ADT6) and cycli  peptides (i.e., ADTC5 
and ADTC6) were compared to those of a negative control (HBSS medium) in the junction-
resealing assay using MDCK cell monolayers (Figure 1). In this assay, intercellular junctions 
were opened upon temporarily removing calcium ions from the medium. Under this condition, 
calcium-dependent junctional proteins are unable to form homotypic interactions in the adherens 
junctions; as a result, the TEER values drop upon opening of the intercellular junctions. After 1 
hour, the junctions can be resealed upon addition of calcium ions into the medium. During the 
resealing, the peptide was added to determine its ability to block calcium-dependent cadherin-
cadherin interactions. When the peptide blocks the cadherin-cadherin interactions, the resealing 
of the intercellular junctions is inhibited; as a result, the TEER values of the monolayers do not 
return to their original values as they do in HBSS (negative control). 
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Figure 1: Effect of incubation time on percent change of TEER values during resealing inhibited 
by 1.0 mM of ADT6, ADTC5, and ADTC6 at different time points (4h to 6h). Linear ADT6 
produced significantly lower resealing compared to HBSS at 4h, 5h and 6h (p<0.05) time points. 
ADTC5 caused a significantly lower percent of resealing compared to HBSS at time points 4h, 
5h, and 6h (p<0.05). ADTC6 did not have any difference in percent of resealing compared to 
HBSS at any time point. Significant differences were observed between ADT6 and ADTC6 and 
between ADTC5 and ADTC6 at a concentration of 1.0 mM at 4h and 5 h time points (p <0.02). 
Generally, there was no significant difference between linear ADT6 and ADTC5 at 1.0 mM 
concentration. The experiments were done in triplicate, and the valus re the mean ± SE. Star 
(*) means significantly different from HBSS; number sign (#) means significantly different from 
1.0 mM ADTC6. 
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At 1.0 mM concentration, linear ADT6 and cyclic ADTC5 have comparable inhibitory 
activity in inhibiting junction resealing from the 4h to the 6h time point (p<0.05). This suggests 
that cyclization does not increase or abolish the activity of ADTC5. he activity of 1.0 mM 
ADT6 and ADTC5 is significantly different from that of 1.0 mM ADTC6 (p<0.01). In contrast, 
there is no significant difference between ADTC6 and HBSS, suggestin  that ADTC6 does not 
have the ability to inhibit resealing of the intercellular junctions (Figure 1). This signifies the 
importance of some residues in the peptide. The inactivity of 1.0 mM ADTC6 was also seen in 
another experiment when it was compared to a negative control KKLVPR, which is derived from 
another cell adhesion protein called intercellular adhesion molecule-1 (ICAM-1) (data not 
shown). 
The activity of ADTC5 peptide at two different concentrations (0.5 and 1.0 mM) was 
compared to that of a control peptide (KKLVPR) (Figure 2). A trend showing that KKLVPR 
causes a lower percentage of resealing compared to HBSS was observed; however, there was no 
statistically significant difference between HBSS and KKLVPR treatments (p>0.05) at the 6h 
time point. The activity of 1.0 mM ADTC5 was significantly different from that of both 1.0 mM 
KKLVPR (p<0.05) and HBSS (p < 0.01), confirming that ADTC5 has specificity for E-cadherin 
in the intercellular junctions. Although there was a trend to show that the inhibitory activity of 
1.0 mM ADTC5 is better than that of 0.5 mM ADTC5, there was no statistically significant 
difference between their activities at the 6h time point. This finding suggested that 0.5 mM of 
ADTC5 might have saturated the site of binding of the protein receptors (i.e., E-cadherin); this 
proposal was confirmed later during concentration-dependent study. 
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Figure 2: Inhibitory activity for junction resealing of ADTC5 (0.5 and 1.0mM) compared to 1.0 
mM control peptide (KKLVPR) and HBSS in MDCK monolayers. At the 6h time point, the 
ADTC5 peptide (at 0.5 and 1.0 mM) blocks the resealing of MDCK cellmonolayers 
significantly better than 1.0 mM KKLVPR peptide and HBSS. There is no significant difference 
between KKLVPR and HBSS (p>0.05). No significant difference in activity was observed 
between 1.0 mM and 0.5 mM of ADTC5 at any time points (p>0.05). A star symbol (*) means 
significantly different from HBSS; a number sign (#) means significantly different from 1.0 mM 
KKLVPR. 
  
11 
 
 
 
 
 
Figure 3: Comparison of the biological activity of ADTC1 and ADTC5 to that of a negative 
control (KKLVPR). The biological activities of 0.5 mM ADTC1 (∆), 1.0 mM ADTC1 (×) and 
1.0 mM ADTC5 () were significantly different from that of KKLVPR (). There is no 
significant difference between 1.0 mM ADTC5 and1.0 mM ADTC1 at any time points. There is 
no significant difference between the activity of 0.5 mM ADTC1 and 1.0 mM ADTC1 from 3–6 
h time points (p>0.05). A star symbol (*) means a significant difference from 1.0 mM KKLVPR. 
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The activities of the cyclic peptides were compared to find the best peptide for in situ rat 
brain perfusion studies (Figure 3). First, the activity of ADTC1 at two different concentrations 
(0.5 and 1.0 mM) was compared to that of 1.0 mM ADTC5 and 1.0 mM KKLPVR (a neg tive 
control). ADTC1 effectively inhibits the junction resealing compared to the negative control. 
There was a trend indicating that ADTC5 may be a better inhibitor than ADTC1 (p<0.34) and 
that the activity of ADTC1 is concentration-dependent (p<0.14). 
3.2. IC50 determination of ADTC5 
Because ADTC5 is the best peptide thus far, the concentration-dependent activity was 
investigated to determine its IC50 compared to that of a negative control peptide (KKLVPR). In 
this case, different concentrations of ADTC5 and KKLVPR were added into cell monolayers and 
the TEER values were measured up to the 6 h time point. The TEER value of peptide was 
compared to that of HBSS to determine the percent of resealing, which is assumed to be 100%. 
The results showed that inhibition by ADTC5 was saturated at concentrations above 0.4 mM 
with resealing only up to 26%, and the IC50 of ADTC5 was observed at a concentration around 
0.3 mM. In contrast, KKLVPR had no significant activity in inhibiting the resealing compared to 
the HBSS medium at any concentration. Previous experiments (Figure 2) also confirmed that up 
to 1.0 mM KKLVPR did not have activity significantly different from that of HBSS medium (p 
>0.05). 
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Figure 4: The concentration-dependent activity of ADTC5 (●) and KKLVPR (∆) to inhibit the 
junction resealing of MDCK cell monolayers. Each data point represents the relative TEER 
values between the peptide-treated and medium-treated cell monolayers ft r 6 hours 
intercellular junction resealing. The value is mean ± SE of six replicates. The inhibition of 
MDCK resealing by ADTC5 was saturated at a concentration of 0.4 mM, and KKLVPR did not 
affect the resealing up to a concentration of 0.7 mM. 
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3.3. The activity of ADTC5 to enhance the delivery of paracellular marker molecules to the 
brain in in situ rat brain perfusion model 
The ability of ADTC5 to open the BBB was evaluated in enhancing 14C-mannitol 
transport to the brain in an i situ rat brain perfusion model. ADTC5 at concentration 1.0 mM 
can enhance the transport of mannitol 1.93-fold compared to vehicle control (p<0.01) as shown 
in Figure 5. As a positive control, linear SHAVAS with the same concentration as ADTC5 was 
able to improve the delivery of mannitol about 1.70-fold compared to control vehicle (p<0.02). 
There was a trend showing that cyclic ADTC5 may have better modulatory activity than linear 
SHAVAS (p<0.40); however, further studies need to be carried out to evaluate the difference 
between these two peptides. 
To evaluate the limit of pore size opening created by ADTC5, the BBB permeation of 
large paracellular marker molecules (i.e., 3H-PEG-1500 and 14C-PEG-40000) in in situ rat brain 
perfusion was determined in the presence and absence of ADTC5 peptide. There was no 
significant difference between the transport of PEG-1500 in the presnc  and absence of ADTC5 
peptide (Figure 6); the Kin values of PEG-1500 with or without peptide were 0.34×10–3 and 0.42 
× 10–3 ml.min–1.gram–1, respectively. Similarly, there was no significant differenc  in the 
transport of PEG-40000 in the presence and absence of ADTC5 peptide (Figure 6); the Kin values 
of PEG-40000 with or without peptide were 0.07 × 10–3 and 0.08 × 10–3 ml.min–1.gram–1, 
respectively. As expected due to their respective size, the Kin of PEG-1500 is higher than that of 
PEG-40000. As a perspective, the Kin values in this study using rat as a model are slightly higher 
than those of PEG-4000 in guinea pig, which is 0.004 × 10–3 ml.min–1.gram–1 [18].  
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Figure 5: Level of radioactive 14C-mannitol in the brain after in situ rat brain perfusion. The 
brain was perfused with 1.0 mM of peptide prior to delivery of 10 ml of14C-mannitol1 µCi/ml at 
a rate of 5 ml/min. The value was the mean ± SE of three replications. The star indicates a 
significant difference from the vehicle. 
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Figure 6: K in of 
3H-PEG-1500 and 14C-PEG-40000 calculated after perfusion with or without 
perfusion of ADTC5 peptide. ADTC5 1.0 mM was perfused at a rate of 5 ml/min for 2 min 
followed by a 2 minute perfusion of 1.0 µCi/ml radioactive PEG at the same rate. The 
experiment was done in triplicate. Kin value was the mean ± SE. There was no significant 
improvement in PEG-1500 and PEG-40000 transport to the brain with or without peptide 
(p >0.05). 
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4. DISCUSSION 
In the last decade, linear ADT6 peptide derived from the counter sequence of HAV 
peptide on the EC1 domain of E-cadherin was found to modulate the intercellula  junctions of 
colorectal adenocarcinoma-2 (Caco-2) and MDCK cell monolayers. ADT peptide increases the 
porosity of intercellular junctions, which is reflected by the decrease in TEER values and 
improvement of apparent permeability (Papp) of 
14C-mannitol through the MDCK monolayers 
[15]. Therefore, this study was designed to improve the biological activity as well as the 
chemical and biological stability of ADT peptides. Several ways to improve the activity and 
metabolic stability include formation of cyclic ADT peptides and creating derivatives of cyclic 
ADT peptide via residue mutation and/or deletion. In this study, three cyclic peptides (i.e., 
ADTC1, ADTC5, and ADTC6) were synthesized and evaluated for their ability to inhibit 
junction resealing of MDCK monolayers. The ability of the best cycli  peptide (i.e., ADTC5) to 
improve transport of paracellular markers (i.e., mannitol, PEG-1500, and PEG-40000) was 
determined. 
In the resealing assay of MDCK monolayers, conversion of linear ADT6 (ADTPPV) to 
cyclic peptides (i.e., ADTC1 and ADTC5) maintains its bioactivity in inhibiting the junction 
resealing. Previous studies have shown that formation of cyclic peptides could enhance or 
maintain their biological activity and/or chemical stability [19]; however, formation of cyclic 
peptides could result in a loss of activity due to formation of an unfavorable conformation for 
binding to the receptor [20]. In this study, deletion of the alanine residu  from ADTC1 to make 
ADTC5 (CDTPPVC) did not affect the biological activity (Figure 3), suggesting that the alanine 
residue is not important for peptide activity or its binding to E-cadherin. Another possible 
explanation is that the side chain of the N-terminus cysteine residue could act as a substitute for 
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the side chain of the alanine residue that binds to the hydrophobic pocket of EC-domain of E-
cadherin. ADTC5 peptide inhibits junction resealing in a concentration-depen nt manner with 
saturation around 0.4 mM concentration; the IC50 of inhibition is around 0.3 mM (Figure 4). 
Furthermore, deletion of C-terminus valine residue in ADTC5 generates cyclic ADTC6 peptide 
(CDTPPC); unfortunately, ADTC6 peptide lost its biological activity completely, indicating that 
the valine residue is an important residue for the biological activity and for its binding to E-
cadherin.  
ADTC5 peptide at concentration 1.0 mM significantly enhances BBB permeation of 14C-
mannitol (1.93-fold) in an in situ rat brain perfusion model compared to vehicle; it has activity to 
enhance transport similar to that of a positive control, HAV peptide (Ac-SHAVAS-NH2) 1.0 
mM, which produces 1.70-fold transport enhancement compared to vehicle control. To evaluate 
the pore-size limit of the intercellular junction opening mediate by ADTC5 peptide, the 
transport of PEG-1500 and PEG-40000 was evaluated in the absence and presence of p ptide in 
in situ rat brain perfusion model. A very large opening of the intercellular j nctions of the BBB 
by cadherin peptides may create a problem of diffusion of unwanted large proteins, particles, and 
immune cells into the central nervous system (CNS) to create brin toxicity. There was no 
significant enhancement of BBB transport PEG-1500 and PEG-40000 (p> .05) in the presence 
of ADTC5 compared to a vehicle negative control, indicating that, using the current 
experimental conditions, the pore opening caused by ADTC5 does not allow molecules the size 
of PEG-1500 or larger to pass through the BBB. It should be noted that the pplication of 
ADTC5 for two minutes may be too short a time to create large size pore openings that would 
allow enhancement of permeation of PEG-1500 through the BBB. There is a po sibility that 
lengthening the peptide incubation time may increase the paracellulr pore size opening; this is 
19 
 
currently under investigation. Due to the hydrogen-bonding potential of PEG molecules, the 
hydrodynamic radius of PEG-1500 or PEG-40000 is larger than the size of the molecule itself; 
for example, PEG-40000 has a hydrodynamic radius 14 times bigger lar than the actual radius 
of the molecule alone [21]. Therefore, other types of molecules with different sizes and shapes 
should also be used to estimate the limits of pore size openings in the tercellular junctions of 
the BBB mediated by cyclic ADTC5 peptide. 
As shown previously, opening of paracellular pathways may also be useful in nhancing 
BBB permeation of hydrophobic drugs that are subjected to the P-glycoprotein (PgP) efflux 
pump. Modulation of the intercellular junctions with HAV peptide has an effect similar to 
blocking the efflux pumps by delivering daunomycin into the brain in the in situ rat perfusion 
model. Saturating PgP with verapamil in combination with opening of paracellul r pathways by 
the HAV peptide can improve brain delivery of daunomycin up to five fold [16]. In the future, 
ADTC5 will also be investigated for enhancing BBB permeation of drugs that are recognized by 
efflux pumps. Recently, opening of the BBB by cadherin peptides to enhance BBB molecule 
permeation was also confirmed by magnetic resonance imaging (MRI) experiments. In this case, 
MRI detects the amount of gadolinium-DTPA (Gd-DTPA) complex thatenters the brain upon 
peptide treatment in an in situ rat brain perfusion model. The result showed that there was a 
significant enhancement of Gd-DTPA in the brain upon peptide treatment compared to control 
vehicle; this result confirms the bioactivity of cadherin peptides in enhancing 14C-mannitol 
transport into the brain.  
The proposed mechanism of action of cadherin peptides is that they bind to the 
extracellular (EC) domain of E-cadherin to block cadherin-cadherin interactions. From NMR and 
X-ray structural studies, each EC repeat domain (EC1 through EC5) has been shown to have 
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similar beta-barrel structure with a high level of sequence homology [22]. Each EC domain 
contains a bulge and a groove region, and we propose that cadherin peptide can bind to either 
region of each EC domain. Molecular modeling studies suggest that ADT peptides bind to the 
groove region of the EC1 domain of E-cadherin where the HAV sequence r sides [15]; it is 
hypothesized that the side chain of valine in ADT peptide is anchored t  the hydrophobic pocket 
of the groove region of the EC1 domain of E-cadherin. Recently, our NMRstudies indicated that 
ADTC5 and ADTC1 bind to the expressed 15N-labeled EC1 domain of E-cadherin. Both of these 
peptides caused changes in chemical shifts of 1H and 15N of several residues within the EC1 
domain. NMR studies also showed that HAV peptide (Ac-SHAVSS-NH2) binds to the EC1 
domain of E-cadherin at a different site than do ADT peptides; thi conclusion was drawn 
because resonances from different residues were shifting when EC1 was titrated with the HAV 
peptide compared to when titrated with ADT peptides. It is possible that the mechanism of action 
of ADT and HAV peptides is due not only to binding to EC1 but also to simultaneous binding to 
different EC domains (EC1, EC2, EC3, EC5, and EC5) within E-cadherin. Previously, NMR and 
FTIR studies showed that Ac-SHAVSS-NH2 and Ac-TYRIWRDTAN-NH2 (BLG4 from the 
bulge region of EC4) peptides bind to the EC5 domain of E-cadherin, suggestin  that the 
mechanism of action of cadherin peptide is not only via binding to one repeat domain of E-
cadherin [23]. The NMR and molecular docking data also suggest that these two peptides bind to 
different region of EC5; this is consistent with the proposal that a peptide from the groove region 
such as Ac-SHAVSS-NH2 can bind to the bulge region of the EC domains (i.e., EC1 and EC5). 
In contrast, peptides from the bulge region such as BLG4 can bind to the groove region of the 
EC domain (i.e., EC1 and EC5). In the future, we will compare the binding characteristics of 
HAV and ADT peptides to other EC domains (EC2, EC3, and EC4). 
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In cell culture, binding of E-cadherin peptide causes changes in gene expression of E-
cadherin protein expressionin Caco-2 cell monolayers. Although the expression was not altered 
up to 8 hours after exposure, E-cadherin expression declined 24 hours after peptide exposure and 
the expression came back up to 90% after 48 hours [24]. The decline of E-cadherin expression 
was found to be similar upon peptide treatment of MDCK cells [14]. The inhibition of homotypic 
interaction could be correlated with the internalization of E-cadherin, which promotes E-cadherin 
degradation in cytosol. The disappearance of E-cadherin from the cell surface was correlated 
with the gene expression of F-box and leucine-rich repeat protein 4, which encodes the 
component of E3 ubiquitin ligase that has a role in E cadherin endocytosis [24]. Although tight 
junctions are above the adherens junction where the E-cadherin resides, the ffect of peptide in 
the expression and internalization of E-cadherin could modulate the interaction of tight junction 
proteins (i.e., claudins and occludins) to increase paracellular porosities. It has been shown that 
adherens junctions are connected to tight junctions via tight junction proteins ZO-1 and α-catenin 
[25]; there is possible crosstalk between adherens junctions and tight junctions through 
connections of cytoskeletal proteins. 
Because the vascular endothelial cells of the BBB contain N- and VE-cadherin, it is still a 
question whether cadherin peptides from E-cadherin could also bind and modulate VE cadherin 
interactions. It was confirmed that VE-cadherin is responsible for homotypic interactions while 
N-cadherin’s role might be that of anchoring vascular endothelial cells to its surrounding cells 
[26]. Our previous studies indicated that fluorescence-labeled HAV peptide and anti-E-cadherin 
antibody bind to and decorate the intercellular junctions of bovine-brain microvessel cell 
(BBMEC) monolayers, suggesting the presence of E-cadherin. Another possibility is that the 
anti-E-cadherin antibody cross-reacts with VE-cadherin in BBMEC as was seen in the BBMEC 
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aggregation studies [27]. The question is why E-cadherin peptides were able to improve mannitol 
transport in in situ rat brain perfusion even though it was suggested that only N- and VE-
cadherin are available in the endothelial cells of the BBB. Althoug ADT sequences were not 
available in N- and VE-cadherin, the HAV sequence does exist in E-and N-cadherin peptides 
(AHAVSS and AHAVDI, respectively) [28, 29] while VE-cadherin has AVIVDK for its 
sequence homology. The presence of HAV sequence homology in the groove regions of N-
cadherin and VE-cadherin suggests that ADT peptide may still bind to VE- or N-cadherin to 
modulate the BBB. We are currently expressing the EC1 domain of VE-cadherin to evaluate 
whether HAV and ADT peptides can bind to the EC1 domain of VE-cadherin. These binding 
studies will be carried out using NMR and other spectroscopic methods (i.e., fluorescence and 
FTIR).  Furthermore, the binding affinities of HAV and ADT peptides to the EC1 domain of E- 
and VE-cadherin will be compared. 
Other peptides have also been explored for improving the paracellular permeation of 
molecules across the BBB. We found that BLG4peptide from the EC4 of E-cadherin could also 
modulate cadherin-cadherin interactions [16]. H-SWELYYPLRANL-NH2peptide was reported 
to disrupt the integrity of cell monolayers and inhibit the aggregation of cells that expressed only 
E-cadherin (MCF-7 cell) and N-cadherin (MDA-MB35 cell) [30]. In addition to cadherin 
peptides, some peptides were also designed to modulate the interaction of other junctional 
proteins. Cell adhesion recognition (CAR) sequence of occluding was identified as LYHY; linear 
and cyclic LYHY peptides have been shown to inhibit the adhesion of fibroblast cells transfected 
with occludin [31]. A twenty-seven amino acid peptide derived from the first loop of claudin-1 
can improve the in vitro cell permeation of 3 KDa FTIC-dextran. However, its effect on mannitol 
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and lactulose gastrointestinal transport in vivo was less dramatic; this is probably due to the rapid 
metabolism of the peptide in vivo[32].  
The alteration of cytoskeleton rearrangement can also be used to disrupt the BBB. Instead 
of inhibiting junctional protein-protein interactions, another effort to m dulate the biological 
barriers is by relocating the intercellular junction proteins. Protein kinase-Cζ (PKCζ) is 
responsible for protein relocation via binding directly to occludin and phosphorylati n of 
occludin at the following residues: Thr438, Thr403, Thr404, and Thr424. Application of PKCζ
pseudosubstrate (Myr-SIYRRGARRWRKL) reduces the state of occludin phosphorylation and 
affects occludin redistribution in the tight junctions[33]. This disrupts the tight junction integrity 
as observed by the lowering of TEER values and increased inulin transport across MDCK 
monolayers. An FDA-approved adenosine agonist (Lexiscan) can alter RhoA and Rac1 and 
cause cellular cytoskeleton rearrangement accompanied by reduced expression of occludin, 
claudin-5, and ZO-1 from cell surfaces [34]. AT1002 peptide was also found t  modulate the 
intercellular junctions of Caco-2 and the BBB cell monolayers; thi peptide redistributes ZO-1 
from the tight junctions upon tyrosine phosphorylation of ZO-1 via Src kinase activation. 
Removal of AT1002 was accompanied by recovery of unphosphorylated ZO-1 to normal levels 
[35] .These approaches have not yet been successful in the clinic in improv ng drug delivery 
through the BBB; this is due to many factors, including (a) lack of peptide stability in vivo, (b) 
lack of modulatory selectivity, and (c) limited understanding of their mechanisms of action. 
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5. CONCLUSIONS 
 We have discovered cyclic ADT peptides that retain their activity compared to the parent 
linear ADT6 in modulating intercellular junctions in vitro and in situ rat brain perfusion 
models. This study also showed that the C-terminus valine residue is an important residue for the 
biological activity of ADT peptide. The opening of the BBB by ADTC5 is limited to molecules 
with molecular weight less than 1500 daltons. In the future, we will study the activity of ADTC5 
peptide to improve brain delivery of drugs recognized by PgP efflux pumps. The binding site of 
cyclic ADT peptides to EC1 of E-cadherin will also be determined using 3D NMR and 
molecular modeling studies. Finally, binding of ADT peptides to VE-cadherin will be also be 
confirmed by NMR studies. 
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